Publication:
FUS (fused in sarcoma) is a component of the cellular response to topoisomerase I-induced DNA breakage and transcriptional stress.

dc.contributor.authorMartinez-Macias, Maria Isabel
dc.contributor.authorMoore, Duncan Aq
dc.contributor.authorGreen, Ryan L
dc.contributor.authorGomez-Herreros, Fernando
dc.contributor.authorNaumann, Marcel
dc.contributor.authorHermann, Andreas
dc.contributor.authorVan Damme, Philip
dc.contributor.authorHafezparast, Majid
dc.contributor.authorCaldecott, Keith W
dc.date.accessioned2024-10-23T10:07:12Z
dc.date.available2024-10-23T10:07:12Z
dc.date.issued2019-02-26
dc.description.abstractFUS (fused in sarcoma) plays a key role in several steps of RNA metabolism, and dominant mutations in this protein are associated with neurodegenerative diseases. Here, we show that FUS is a component of the cellular response to topoisomerase I (TOP1)-induced DNA breakage; relocalising to the nucleolus in response to RNA polymerase II (Pol II) stalling at sites of TOP1-induced DNA breaks. This relocalisation is rapid and dynamic, reversing following the removal of TOP1-induced breaks and coinciding with the recovery of global transcription. Importantly, FUS relocalisation following TOP1-induced DNA breakage is associated with increased FUS binding at sites of RNA polymerase I transcription in ribosomal DNA and reduced FUS binding at sites of RNA Pol II transcription, suggesting that FUS relocates from sites of stalled RNA Pol II either to regulate pre-mRNA processing during transcriptional stress or to modulate ribosomal RNA biogenesis. Importantly, FUS-mutant patient fibroblasts are hypersensitive to TOP1-induced DNA breakage, highlighting the possible relevance of these findings to neurodegeneration.
dc.format.number2es_ES
dc.format.volume2es_ES
dc.identifier.doi10.26508/lsa.201800222
dc.identifier.e-issn2575-1077es_ES
dc.identifier.journalLife science alliancees_ES
dc.identifier.otherhttp://hdl.handle.net/10668/13629
dc.identifier.pubmedID30808650es_ES
dc.identifier.urihttps://hdl.handle.net/20.500.12105/25248
dc.language.isoeng
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshA549 Cells
dc.subject.meshAmyotrophic Lateral Sclerosis
dc.subject.meshAnimals
dc.subject.meshBinding Sites
dc.subject.meshBrain
dc.subject.meshChromatin
dc.subject.meshDNA Breaks, Double-Stranded
dc.subject.meshDNA Repair
dc.subject.meshDNA Topoisomerases, Type I
dc.subject.meshFibroblasts
dc.subject.meshHeLa Cells
dc.subject.meshHumans
dc.subject.meshMice
dc.subject.meshMutant Proteins
dc.subject.meshMutation
dc.subject.meshNeural Stem Cells
dc.subject.meshNeurons
dc.subject.meshRNA Polymerase I
dc.subject.meshRNA Polymerase II
dc.subject.meshRNA-Binding Protein FUS
dc.subject.meshTranscription, Genetic
dc.titleFUS (fused in sarcoma) is a component of the cellular response to topoisomerase I-induced DNA breakage and transcriptional stress.
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files